iBio to gain U.S. patent for novel influenza therapeutic product
"The antibody covered by this patent is designed to block critical functions of the influenza virus necessary for virus replication," Wayne P. Fitzmaurice, Ph.D., iBio's vice president of intellectual property, said. "Current public health strategies for influenza include annual preventative vaccination and in some cases, the use of small molecule drugs for treatment of infected individuals. However, because preventive vaccination reaches only a part of the population, vaccines vary in effectiveness to prevent disease, and drug-resistant influenza strains pose increased risk, there is a global need for new, more effective therapeutic biologics that block the replication of influenza virus directly in those who become infected."
Under the notice, the patent will be US 9,155,201 under the title of “Human Neuraminidase Antibody and Methods of Use Thereof.” It suggests using a monoclonal antibody to treat influenza infections by attacking the influenza neuraminidase protein.
"This patent is an important addition to our portfolio of intellectual property covering infectious disease product applications of our core pharmaceutical technology, the iBioLaunch platform," iBio President Robert Erwin said. "In addition to using our technology to advance our proprietary product candidates for treatment of chronic fibrotic diseases to clinical trials, our iBioLaunch platform is being applied to antibodies and antibody fusion proteins to target pathogens such as influenza, Ebola virus, anthrax and others for which it provides technical and economic advantages for product optimization and commercial manufacturing."